D-0376-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0376-2021 was initiated by Teva Pharmaceuticals USA on Apr 26, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 7,564/1 multiple dose vial per carton.

Recall details

Product Type
Drugs
Report Date
May 26, 2021
Initiation Date
Apr 26, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7,564/1 multiple dose vial per carton

Product description

Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, 10 mL Multiple Dose Vial, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454 NDC 0703-0045-01

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed nationwide.

Code information

Lot # 31327989B, exp. date 04/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0376-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0376-2021. Report a data issue: hello@regdatalab.com.